Genetic variation within the glycoprotein B and H genes of human cytomegalovirus in solid organ transplant recipients

2007 ◽  
Vol 9 (1) ◽  
pp. 73-77 ◽  
Author(s):  
L. Zhou ◽  
J. Fan ◽  
S.S. Zheng ◽  
W.H. Ma
Keyword(s):  
Genetic Variation ◽  
Human Cytomegalovirus ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Glycoprotein B ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Solid Organ Transplant Recipients

scholarly journals Long-Term Persistence of Immunoglobulin A (IgA) and IgM Antibodies against Human Cytomegalovirus in Solid-Organ Transplant Recipients

1999 ◽  
Vol 6 (4) ◽  
pp. 621-623 ◽  
Author(s):  
Bodo R. Eing ◽  
Horst G. Baumeister ◽  
Joachim E. Kuehn ◽  
Guenter May
Keyword(s):  
Human Cytomegalovirus ◽  
Immunoglobulin A ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Solid Organ Transplant Recipients

ABSTRACT The retrospective analysis of 494 solid-organ transplant recipients revealed that during the follow-up period (mean duration, 3.2 years) 184 (88%) of 209 anti-human cytomegalovirus (HCMV) immunoglobulin A (IgA)-positive patients remained IgA positive, as did 128 (74.85%) of 171 anti-HCMV IgM-positive patients. We conclude that anti-HCMV IgA and IgM testing for management of clinically relevant HCMV infections in solid-organ transplant recipients is dispensable.

scholarly journals Rising Levels of Human Cytomegalovirus (HCMV) Antigenemia during Initial Antiviral Treatment of Solid-Organ Transplant Recipients with Primary HCMV Infection

1998 ◽  
Vol 36 (4) ◽  
pp. 1113-1116 ◽  
Author(s):  
Giuseppe Gerna ◽  
Maurizio Zavattoni ◽  
Elena Percivalle ◽  
Paolo Grossi ◽  
Maria Torsellini ◽  
...  
Keyword(s):  
Human Cytomegalovirus ◽  
Hcmv Infection ◽  
Antiviral Treatment ◽  
Antiviral Drug ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Solid Organ Transplant Recipients

In 7 of 18 solid-organ transplant recipients with primary human cytomegalovirus (HCMV) infection, HCMV antigenemia levels were unexpectedly found to rise significantly (P = 0.018) during a mean time of 7.3 ± 3.2 days after initiation of specific antiviral treatment, whereas corresponding levels of viremia dropped significantly (P = 0.043). Thus, shifting to an alternative antiviral drug based solely on increasing antigenemia levels is not justified in this group of patients.

Sign in / Sign up

Export Citation Format

Share Document